To see the other types of publications on this topic, follow the link: CHR 2013.
Journal articles on the topic 'CHR 2013'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'CHR 2013.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Seckin, Turgay, Ayber Yildirim, and Suleyman Koytepe. "Synthesis and properties of novel high thermally stable polyimide-chrysotile composites as fire retardant materials." Journal of Polymer Engineering 34, no. 9 (2014): 793–802. http://dx.doi.org/10.1515/polyeng-2013-0255.
Full textAbstract:
Abstract Novel high thermally stable polyimide-chrysotile (PI-Chr) composites were synthesized. Firstly, Chrysotile (Chr) was modified with 3-aminopropyltriethoxysilane (APS). Poly(amic acid) solution was synthesized from pyromellitic dianhydride (PMDA) and 4,4′-diaminodiphenyl ether. Then, PI-Chr composites were prepared from poly(amic acid) solution and different ratios of modified Chr. Prepared PI-Chr composites were characterized by Fourier transform infrared (FTIR) spectroscopy, X-ray spectroscopy and thermal analysis techniques. Thermal analysis results showed that the PI-Chr composites have higher decomposition temperatures in comparison with the pure PIs. A 10% weight loss belonging to PI-Chr composites was observed between 489°C and 536°C in air atmosphere, but this value was 468°C in air for pure PIs. The glass transition temperatures (Tg s) of the PI-Chr composites were 373°C–384°C, depending upon the amount of the Chr. PI-Chr composites exhibited improved thermal stability. The activation energies (Ea s) of the thermal degradation reaction were calculated using the Kissinger method for pure PI and composites. The Ea s of the PI-Chr composites were found to be 77 and ∼117 kJ/mol. The fire retardant properties of Chr in the PI matrix were also tested by the total heat release test. The introduction of Chr in the composites leads to a slight increase in fire retardant properties thermal stability.
2
Petersen, Anders Klostergaard. "Platon til tre generationer." Religionsvidenskabeligt Tidsskrift, no. 61 (August 18, 2015): 122. http://dx.doi.org/10.7146/rt.v0i61.21960.
Full textAbstract:
En reviewartikel om den nye danske Platon-oversættelsePlaton III. Samlede værker i ny oversættelse. Hipparchos, Rivalerne, Theages, Charm-ides, Laches, Lysis, Euthydemos, Protagoras, Gorgias, Menon, Den store Hippias, Den lille Hippias. Udgivet af Jørgen Mejer og Chr. Gorm Tortzen. (Gyldendal, 2011)Platon IV. Samlede værker i ny oversættelse. Ion, Menexenos, Kleitophon, Staten I-X, Timaios, Kritias, Minos. Udgivet af Jørgen Mejer og Chr. Gorm Tortzen. (Gyldendal, 2013)
3
Humm, Michel, Rose-Marie Arbogast, Dominique Beyer, et al. "Chronique d'Archimède : Bilan des activités scientifiques 2013-2014 de l’unité mixte de recherche 7044." Archimède. Archéologie et histoire ancienne 1 (2014): 147–82. http://dx.doi.org/10.47245/archimede.0001.chr.01.
Full text
4
Alberti, Marco, Marco Gavanelli, and Evelina Lamma. "The CHR-based Implementation of the SCIFF Abductive System." Fundamenta Informaticae 124, no. 4 (2013): 365–81. http://dx.doi.org/10.3233/fi-2013-839.
Full text
5
Currie, Shawn R., Kirsten Fiest, and Lindsay Guyn. "Using Community-Level Mental Health Surveillance Data to Examine the Relationship of Depression Prevalence to Social Determinants of Health and Access to Mental Health Services." Canadian Journal of Community Mental Health 32, no. 1 (2013): 43–57. http://dx.doi.org/10.7870/cjcmh-2013-005.
Full textAbstract:
The effect of social determinants of health on depression prevalence and treatment access was examined using community survey and administrative data on mental health service users in the Calgary Health Region (CHR). Consistent with national prevalence data, depression was significantly associated with female gender, younger age, and health risk factors such as smoking, hypertension, and obesity. The prevalence of depression causing interference in daily functioning across 19 social districts (subregions within the CHR) was significantly related to community-level indicators of single-parent status, low-income families, and low educational achievement in each district. Disparities in treatment access were also found with persons living in the most impoverished districts having the lowest rates of accessing professional mental health services.
6
Marques da Silva, Ana. "Beneath and Beyond the Code." Matlit Revista do Programa de Doutoramento em Materialidades da Literatura 3, no. 1 (2015): 251–55. http://dx.doi.org/10.14195/2182-8830_3-1_17.
Full text
7
Labelle, Kathryn. "The OrendaThe Orenda. Joseph Boyden. Toronto: Hamish Hamilton, 2013. Pp. 496, $32.00 paper." Canadian Historical Review 96, no. 3 (2015): 426–29. http://dx.doi.org/10.3138/chr.96.3.br02.
Full text
8
Suari, Ni Made Rini, Ketut Ariawati, and Nyoman Adiputra. "Reticulocyte hemoglobin content as a predictor of iron deficiency anemia." Paediatrica Indonesiana 55, no. 3 (2015): 171. http://dx.doi.org/10.14238/pi55.3.2015.171-5.
Full textAbstract:
Background Iron deficiency anemia (IDA) is the most common form of anemia in developing countries, such as Indonesia. Iron deficiency anemia in children is a serious problem because it affects their growth and development. Early detection of IDA and subsequent treatment in childhood may prevent future health problems.Objective To assess the use of reticulocyte hemoglobin content (CHr) to detect IDA in children aged 6-60 months.Methods We performed a cross-sectional study to measure the sensitivity and specificity of CHr compared to serum ferritin which is considered to be the gold standard for IDA diagnosis. The study was conducted from September 2011 to March 2013 in children aged 6-60 months who visited the Pediatric Outpatient Clinic, Sanglah Hospital, and Puskesmas II in West Denpasar. Data analysis was performed by 2x2 table. The results were assessed by area under the curve (AUC) and receiver operating characteristic (ROC).Results Of 121 children underwent blood testing during the study period, 69 children were excluded because they did not have hypochromic microcytic anemia, leaving 52 subjects eligible for the study. The prevalence of IDA in this study was 31%. Reticulocyte hemoglobin content (CHr) ≤ 23.1 pg had 88% (95%CI 71 to 100%) sensitivity and 25% (95%CI 11 to 39%) specificity.Conclusion Reticulocyte hemoglobin content < 23.1 pg may be a good predictor of IDA.
9
Salaverria, Itziar, Idoia Martin-Guerrero, Rabea Wagener, et al. "A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma." Blood 123, no. 8 (2014): 1187–98. http://dx.doi.org/10.1182/blood-2013-06-507996.
Full textAbstract:
Key Points A subset of lymphomas with gene expression and pathological characteristics of Burkitt lymphomas but absence of MYC translocation does exist. These lymphomas carry chr 11q proximal gains and telomeric losses, suggesting co-deregulation of oncogenes and tumor suppressor genes.
10
TENG, W. L., W. J. FENG, J. Y. ZHANG, et al. "Identification of quantitative trait loci underlying lutein content in soybean seeds across multiple environments." Journal of Agricultural Science 155, no. 8 (2017): 1263–71. http://dx.doi.org/10.1017/s0021859617000363.
Full textAbstract:
SUMMARYLutein benefits human health significantly, including that of the eyes, skin and heart. Therefore, increasing lutein content in soybean seeds is an important objective for breeding programmes. However, no information about soybean lutein-related quantitative trait loci (QTL) has been reported, as of 2016. The aim of the present study was to identify QTLs underlying the lutein content in soybean seeds. A population including 129 recombinant inbred lines was developed from the cross between ‘Dongnong46’ (lutein 13·10 µg/g) and ‘L-100’ (lutein 23·96 µg/g), which significantly differed in seed lutein contents. This population was grown in ten environments including Harbin in 2012, 2013, 2014 and 2015; Hulan in 2013, 2014 and 2015; and Acheng in 2013, 2014 and 2015. A total of 213 simple sequence repeat markers were used to construct the genetic linkage map, which covered approximately 3623·39 cM, with an average distance of 17·01 cM between markers. In the present study, eight QTLs associated with lutein content were found initially, which could explain 1·01–19·66% of the observed phenotypic variation in ten different tested environments. The phenotypic contribution of qLU-1 (located near BARC-Satt588 on chromosome 9 (Chr 9; linkage group (LG) K)) was >10% across seven tested environments, while qLU-2 (located near Satt192 of Chr 12 (LG H)) and qLU-3 (located near Satt353 of Chr12 (LGH)) could explain 5–10% of the observed phenotypic variation in more than seven environments, respectively. qLU-5, qLU-6, qLU-7 and qLU-8 could be detected in more than four environments. These eight QTLs were novel, and have considerable potential value for marker-assistant selection of higher lutein content in soybean lines.
11
Heavican, Tayla B., Jiayu Yu, Alyssa Bouska, et al. "Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways." Blood 128, no. 22 (2016): 4096. http://dx.doi.org/10.1182/blood.v128.22.4096.4096.
Full textAbstract:
Abstract Peripheral T-cell lymphoma (PTCL) is a group of clinically and pathologically heterogeneous non-Hodgkin lymphomas (NHL). Using gene expression profiling (GEP), we have defined molecular classifiers for PTCL subtypes reflecting their pathobiology and oncogenic pathways (Iqbal et al. 2014). We have also shown associations of specific mutations with the molecular subgroups (Wang et al. 2015). Although genomic information is increasing, the pathogenetic mechanisms of PTCLs remain largely unknown. Therefore, we analyzed copy number variation (CNV) and GEP to identify unique genetic abnormalities in the defined PTCL molecular subgroups. CNV data were generated on fresh frozen or formalin-fixed paraffin-embedded genomic DNA (n=114) on 3 Affymetrix platforms (SNP 6.0, 250K SNP, and OncoScan). Two published cohorts (PTCL-NOS, Hartmann et al. 2010; ALCL, Boi et al. 2013) were included for validation. The gene expression analysis, morphological review and clinical characteristics of these cases have been included in previous studies (Iqbal et al. 2010, 2014). Angioimmunoblastic T-cell lymphoma (AITL) represents 20% of all PTCL cases. The most recurrent CNV in AITL was chromosome (chr) 5 gain (39%), followed by chr 21 gain (21%). Interestingly, chr 21 gain co-occurred with chr 5 gain (p=0.003). No recurrent losses (≥20%) were identified among these cases. Molecularly re-classified AITL cases from morphologically classified PTCL-NOS cases showed concordant results with bonafide AITL cases. Of the commonly mutated genes, DNMT3A, IDH2, RHOA and TET2, only IDH2R172Kshowed a significant association (p=0.012) with chr 5 gain. GEP showed enrichment of gene signatures associated with oxidative phosphorylation (PGC-1α target genes) in cases with chr 5 gain. PTCL, not otherwise specified (PTCL-NOS) is the most common PTCL subtype and cannot be further sub-classified using conventional approaches; however, we have identified 2 molecular subgroups within PTCL-NOS, the GATA3 and TBX21 subgroups which are related to 2 distinct T-helper subsets (Iqbal et al. 2014), by employing GEP. Consistent with earlier observations (Hartmann et al. 2010), PTCL-NOS showed remarkably varied CNVs with nearly 50% of cases showing high CNV frequencies. When correlated with molecular subgroups, distinctive CNVs were observed in the molecular GATA3 and TBX21 subgroups. The GATA3 subgroup displayed a large assortment of CNVs. Complete or partial gain of chr 7 (57%) was the most recurrent gain in these cases. Losses affecting 17p, 10q and 9p21, encompassing tumor suppressors such as TP53 (57%), PTEN (43%) and CDKN2A (43%), were frequent in the GATA3 subgroup. The TBX21 subgroup had significantly fewer CNVs, as none were recurring (≥20%); but gains of 5p or 11p were observed in 14%. Additionally, PTCL-NOS cases with ≥10% abnormal genome had significantly poorer overall survival (p=0.012) compared to those with fewer abnormalities. This finding validates the GEP molecularly defined subgroups, as the GATA3 subgroup displayed more CNVs and has been associated with a worse prognosis compared to the TBX21 subgroup (Iqbal et al. 2014). We were able to distinguish CNVs characteristic of the different entities, including the co-occurrence of chr 5 and 21 gains specific in AITL. Gain of 1q (complete or partial) was identified in the GATA3 subgroup of PTCL-NOS and anaplastic lymphoma kinase (ALK) (-) ALCL with equal frequencies (~ 36%), but only 16% in ALK(+) ALCL. Complete or partial gain of chr 7 was also observed in ALCL, but at a considerably lower frequency than in the GATA3 subgroup. Additionally, gain of chr 18 or regions of 17q, and loss of 5q or regions on both arms of chr 9, were more frequent in the GATA3 subgroup compared to other entities. The TBX21 subgroup was primarily differentiated from the GATA3 subgroup by presence of fewer CNVs. Our analysis provides a framework for future investigations into the molecular pathogenesis of PTCL, and highlights potential candidate oncogenes and tumor suppressors deregulated by copy number aberrations. Comparative analysis revealed that certain chromosomal abnormalities are entity-specific. AITL cases with IDH2R172K also had trisomy 5 suggesting that these oncogenic events cooperate in malignant transformation. Thus, the complexity of PTCL is finally becoming clearer with the integration of high resolution molecular techniques for global genomic analysis. Disclosures No relevant conflicts of interest to declare.
12
Brown, R. Blake. "The Court of Appeal for Ontario: Defining the Right of Appeal, 1792–2013 / Paths to the Bench: The Judicial Appointment Process in Manitoba, 1870–1950The Court of Appeal for Ontario: Defining the Right of Appeal, 1792–2013. Christopher Moore. Toronto: University of Toronto Press and the Osgoode Society for Canadian Legal History, 2014. Pp. xxi + 325, $55.00 clothPaths to the Bench: The Judicial Appointment Process in Manitoba, 1870–1950. Dale Brawn. Vancouver: UBC Press, 2014. Pp. x + 296, $90.00 cloth, $32.95 paper." Canadian Historical Review 96, no. 3 (2015): 441–45. http://dx.doi.org/10.3138/chr.96.3.br09.
Full text
13
Kang, Matthew, Anargyros Xenocostas, Alejandro Lazo-Langner, et al. "Impact of Transition to Generic Imatinib in the Molecular Response Among Patients with Chronic Myeloid Leukemia." Blood 124, no. 21 (2014): 5527. http://dx.doi.org/10.1182/blood.v124.21.5527.5527.
Full textAbstract:
Abstract Background: The introduction of Imatinib Mesylate (Gleevec™), a tyrosine kinase inhibitor (TKI), has revolutionized the management of Chronic Myeloid Leukemia (CML). Recently, on April 2, 2013, Health Canada approved two generic versions of imatinib mesylate (Apotex and TEVA) for sale in Canada—both of which, have been shown to be bioequivalent to the brand name Gleevec™, with similar serum imatinib levels and area under the curve after oral ingestion. In one of the largest case series reported to date (N=126), it has been reported that complete hematologic response (CHR) was lost in 33% of CML patients who were switched from brand name to generic imatinib. In an effort to assess the generalizability of this claim, we conducted a retrospective review of all patients with CML treated with Gleevec™ at a single tertiary care centre to evaluate whether there was a change in CHR or major molecular responses (MMR) in all patients who were switched to generic imatinib. Method: We retrospectively evaluated adult CML patients who were treated from January 1, 2002 to December 2011 with brand name Imatinib (Gleevec™) and were switched to generic imatinib (Apotex or TEVA) during 2013. Patient-reported side effect profiles were also collected in a subset of patients before and after the change from Gleevec™ to generic. A follow-up period was defined as 12 months from the time of switch from brand name to generic. The primary outcome was a composite of rates of loss of CHR and/or MMR, based on the Canadian Consensus Group of the Management of Chronic Myelogneous Leukemia (CCGM-CML). Secondary outcome include side effect profiles, graded as per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), during the follow-up period. Results: During our study period, a total 71 adult CML patients were identified. Of these, only 30 patients were included in the analysis. Among the 41 patients who were excluded, data could not be retrieved in 23 (32.4%), 9 (12.7%) were on dasatinib, 3 (4.2%) were on nilotinib, 2 (2.8%) were transplanted and 4 (5.6%) had died at the time of the switch. Data was collected using electronic medical records from patient clinic visits. The median age of all included patients was 54 years and 16 (53.3%) were male. The primary endpoint was seen in 2 of 30 patients (6.7%; 95% CI 3.5-25.6). There was a loss of MMR in 1 (3.3%) where the BCR-ABL transcript declined from a 4.19 log reduction to a 2.78 log reduction after switching to TEVA-imatinib. There was a loss of CHR in 1 (3.3%) patient, where a 20 g/L drop in hemoglobin was seen after switching to APO-imatinib. In both patients in whom the primary endpoint was seen, their imatinib dose was 200 mg before and after switching. Further, in both patients, these losses of response were transient. The secondary outcomes will be presented at the meeting. Conclusion: The generic formulations of imatinib used in Canada do not seem to be associated with the same previously reported lack of clinical efficacy when compared to brand name Gleevec™ during a follow-up period of 12 months. Further, a loss of MMR and a loss of CHR were transient in the 2 of 30 patients identified. Despite these infrequent events, treating physicians should consider that a switch to a generic formulation may be a contributing factor for the patient’s loss of MMR or CHR. However, given the wide confidence intervals, larger studies and longer follow up are needed to address this issue. Disclosures No relevant conflicts of interest to declare.
14
Goddard, Peter A. "The Death and Afterlife of the North American MartyrsThe Death and Afterlife of the North American Martyrs. Emma Anderson. Cambridge, MA: Harvard University Press, 2013. Pp. 480, US $39.95 cloth." Canadian Historical Review 96, no. 3 (2015): 429–31. http://dx.doi.org/10.3138/chr.96.3.br03.
Full text
15
French, David. "Unlikely Diplomats: The Canadian Brigade in Germany, 1951–64, by Isabel CampbellUnlikely Diplomats: The Canadian Brigade in Germany, 1951–64. Isabel Campbell. Vancouver:UBCPress, 2013. Pp. 265, $95.00 cloth, $32.95 paper." Canadian Historical Review 96, no. 4 (2015): 624–26. http://dx.doi.org/10.3138/chr.96.4.br14.
Full text
16
Freeman, Victoria. "Mississauga Portraits: Ojibwe Voices from Nineteenth-Century CanadaMississauga Portraits: Ojibwe Voices from Nineteenth-Century Canada. Donald B. Smith. Toronto: University of Toronto Press, 2013. Pp. xxxiv + 457, $85.00 cloth, $37.95 paper." Canadian Historical Review 96, no. 3 (2015): 435–37. http://dx.doi.org/10.3138/chr.96.3.br06.
Full text
17
Deslandres, Dominique. "Along a River: The First French-Canadian Women par Jan NoelAlong a River: The First French-Canadian Women. Jan Noel. Toronto: University of Toronto Press, 2013. Pp. 356, 33.95 $ édition brochée." Canadian Historical Review 97, no. 4 (2016): 585–87. http://dx.doi.org/10.3138/chr.97.4.br05.
Full text
18
Moreau, Bill. "Geographies of the Romantic North: Science, Antiquarianism, and Travel, 1790-1830Geographies of the Romantic North: Science, Antiquarianism, and Travel, 1790-1830. Angela Byrne. New York: Palgrave Macmillan, 2013. Pp. xiv + 266, $90.00." Canadian Historical Review 96, no. 2 (2015): 294–96. http://dx.doi.org/10.3138/chr.96.2.br05.
Full text
19
Ferrari, Anna, Cristina Papayannidis, Carmen Baldazzi, et al. "Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome." Blood 124, no. 21 (2014): 2379. http://dx.doi.org/10.1182/blood.v124.21.2379.2379.
Full textAbstract:
Abstract Background: AML is a heterogeneous disease with various chromosomal aberrations. The karyotype at diagnosis provides important prognostic information that influences therapy and outcome, and patients (pts) with complex karyotype (CK) have generally a poor outcome. TP53 is the most frequently mutated gene in human tumors. The reported TP53 mutation rate in AML is low (2.1%). In contrast, the incidence of TP53 mutations in AML with a complex aberrant karyotype is higher (69-78%). Aims: To investigate the frequency, the types of mutations, the associated cytogenetic abnormalities and the prognostic role of TP53 mutations in adult AML pts, we focused the screening on subgroups of AML with chromosome abnormalities. Patients and Methods: 886 AML patients were analysed at the Seràgnoli Institute of Bologna between 2002 and 2013 for morphology, immunophenotype, cytogenetic and for a panel of genetic alterations (FLT3, NPM, WT1, CBF fusion transcripts, DNMT3A, IDH1, IDH2, etc). Of these, 172 adult AML pts were also examined for TP53 mutations using several methods, including Sanger sequencing, Next-Generation deep-Sequencing (Roche) and HiSeq 2000 (Illumina) platform (35/172 pts). 40 samples were genotyped with Genome-Wide Human SNP 6.0 arrays or with CytoScan HD Array (Affymetrix) and analysed by Nexus Copy Number™ v7.5 (BioDiscovery). Results: Of the 886 AML patients beforehand analysed, 172 pts were screened for TP53 mutations and were correlated with cytogenetic analysis (excluding 15 pts where the karyotype was not available). 1. Fifty-two pts (30,2%) have 3 or more chromosome abnormalities, i.e. complex karyotype; 2. 71 (41,3%) presented one or two cytogenetic abnormalities (other-AML) and 3. 34 pts (19,8%) have normal karyotype. Sanger sequencing analysis detected TP53 mutations on 29 patients with 36 different types of mutations; seven pts (4%) have 2 mutations. Mostly (23/29) of the TP53 mutated pts (79.3%) had complex karyotype while only 6/29 mutated pts have “no CK” (21% and 3% of the entire screened population). Overall, between pts with complex karyotype, TP53 frequency is 44.2%. Regarding the types of the TP53 alterations, 32 were deleterious point mutations (http://p53.iarc.fr/TP53GeneVariations.aspx) and 4 deletions. Forty pts were also analysed for Copy Number Alterations (CNAs) by Affymetrix SNP arrays: several CNAs were found ranged from loss or gain of complete chromosome (chr) arms to focal deletions and gains targeting one or few genes involving macroscopic (>1.5 Mbps), submicroscopic genomic intervals (50 Kbps - 1.5 Mbps) and LOH (>5 Mbps) events. Of relevance, gains located on chr 8 were statistically associated with TP53 mutations (p = 0.001). Seven genes are included in these regions (RGS20, TCEA1, LINC01299, ARMC1, MTFR1, RAD54B, KIAA1429). In addition to the trisomy of the chr 8, others CNAs, located on other chromosomes are significantly associated (p = 0.05) with TP53 mutations: loss of chr 5q, chr 3 (p22.3), chr 12 (p12.3) and the gain of chr 17 (p11.2), chr 16 (p11.2-11.3) and chr 14 (q32.33). The zinc finger gene ZNF705B, implicated in the regulation of transcription was the most differentially associated gene (gain). WES analysis was done in 37 pts, 32 TP53 were wt while 5 pts were TP53 mutated: of importance, CDC27, PLIN4 and MUC4 were found also mutated in 3 out of 5 TP53 mutated (60%). Clinical outcome: as previously reported, alterations of TP53 were significantly associated with poor outcome in terms of both overall survival and disease free-survival (P < 0.0001). Conclusions: Our data demonstrated that TP53 mutations occur in 16.86% of AML with a higher frequency in the subgroup of complex karyotype AML (p< 0.0001–Fischer’s exact test). Since TP53 mutations have predicted to be deleterious and significantly correlated with prognosis, TP53 mutation screening should be recommended at least in complex karyotype AML pts. Furthermore, although further studies in larger numbers of patients are needed, the gain of chromosome 8 was observed to be significantly associated to TP53 mutations pts. Supported by: ELN, AIL, AIRC, PRIN, progetto Regione-Università 2010-12 (L. Bolondi), FP7 NGS-PTL project. Disclosures Martinelli: Novartis: Speakers Bureau; Bristol Mayers Squibb: Speakers Bureau; Pfizer: Speakers Bureau.
20
Barrientos, Jacqueline C., Nina D. Wagner-Johnston, Sven De Vos, et al. "Chemo-Immunotherapy Combination Of Idelalisib With Bendamustine/Rituximab Or Chlorambucil/Rituximab In Patients With Relapsed/Refractory CLL Demonstrates Efficacy and Tolerability." Blood 122, no. 21 (2013): 4176. http://dx.doi.org/10.1182/blood.v122.21.4176.4176.
Full textAbstract:
Abstract Background PI3K-delta signaling is critical for proliferation, survival, homing and tissue retention of malignant B cells. Idelalisib is a selective, oral inhibitor of PI3Kδ that has been previously shown to be safe and tolerable and has demonstrated considerable activity as monotherapy or in combination with other agents in patients with relapsed/refractory (R/R) CLL. We provide an update on the safety and efficacy of a phase 1 study of idelalisib (IDELA) 150mg po BID administered continuously on a 28-day cycle in combination with two chemo-immunotherapy regimens: bendamustine/rituximab (IDELA+BR) and chlorambucil/rituximab (IDELA+ChR). Methods Twenty-nine adult subjects (15/14 IDELA+BR; IDELA+ChR) with R/R CLL requiring treatment were enrolled between April and Aug 2011 for the IDELA+BR cohort and Mar and Jul 2012 for the IDELA+ChR cohort. Median age 64 yrs (Min, Max: 41, 82), gender M/F (%) 65/35, WHO PS (%) 0/1/2 59/38/3, current Binet stage (%) A/B/C 21/28/41, and 62% of subjects had bulky adenopathy (presence of ≥1 node with diameter ≥5 cm). Median number of prior therapies was 3 (Min, Max: 1, 9). Thirty-five percent of subjects had refractory disease (not responding to a standard regimen or progressing within 6 month of the last course of a standard regimen) and 55% of subjects were refractory to rituximab. The treatment schedule was as follows: IDELA+BR (IDELA 150 mg BID po d1-28 until progression or withdrawal, rituximab 375 mg/m2 IV on d1 of cycles 1-6, bendamustine 70 or 90 mg/m2 intravenously on d1 and d2 of cycles 1-6). For the IDELA+RCh cohort (IDELA 150 mg BID po on d1-28 until progression or withdrawal, chlorambucil 10 mg/m2 po once a d1-7 of cycles 1-12, rituximab 375 mg/m2 IV d1 of cycles 1-6). Response was assessed by the investigators based on scheduled CT evaluations and clinical criteria following IWCLL 2008. Results The data cut-off date for this analysis was May 2013. Objective response rates for the 2 cohorts were 89.7% (95% CI (%): 72.6-97.8). Median time to response in both cohorts was 1.9 months. For IDELA+BR, the ORR was 86.7% (95% CI (%): 59.5-98.3) (CR 6.7%, PR 80%), neither median DOR nor median PFS have been reached and median exposure was 18.4 months (Min, Max: 1.2, 24.7). For IDELA+ChR, the ORR was 92.9% (95% CI (%): 66.1-99.8) (CR 14.3%, PR 78.6%), neither median DOR nor median PFS has been reached, and median exposure was 7.7 months (Min, Max: 1.9, 11.1). Commonly reported treatment-emergent AEs (≥20% of all subjects) and lab abnormalities of interest for IDELA+BR were (total(%)/≥grade 3 (%)): pyrexia (46.7/0) diarrhea (26.7/13.3), fatigue (20/0), neutropenia (86.7/60), thrombocytopenia (26.7/6.7), transaminase elevations (26.7/0), anemia (33.3/13.3). For IDELA+ChR, common TEAEs were: pyrexia (57.1/7.1), diarrhea (64.3/7.1), fatigue (42.9/21.4), neutropenia (64.3/42.9), thrombocytopenia (42.9/21.4), transaminase elevations (50.0/21.4), and anemia (42.9/14.3). Conclusion The combination of IDELA+BR or IDELA+ChR is tolerable and demonstrates strong activity with an ORR of 89.7%. Median PFS and DOR have not been reached in the IDELA+BR or the IDELA+ ChR cohorts. The ability to induce responses in this particularly difficult-to-treat patient population with refractory disease, the non-overlapping toxicity with these agents, and the ease of administration makes this an option in this patient population. These results support further studies with these chemo-immunotherapy regimens in patients with CLL. Disclosures: Barrientos: Gilead Sciences: Research Funding. Off Label Use: Idelalisib is a PI3K-delta inhibitor currently in phase III trials for multiple hematologic malignancies. Wagner-Johnston:Gilead Sciences: Research Funding. De Vos:Gilead Sciences: Research Funding. Coutre:Gilead Sciences: Research Funding. Schreeder:Gilead Sciences: Research Funding. Flinn:Gilead Sciences: Research Funding. Sharman:Gilead Sciences: Research Funding. Rai:Gilead Sciences: Research Funding. Leonard:Gilead Sciences: Research Funding. Dansey:Gilead Sciences: Employment. Kim:Gilead Sciences: Employment. Holes:Gilead Sciences: Employment. Adewoye:Gilead Sciences: Employment. Furman:Gilead Sciences: Research Funding.
21
Walker, Barrington. "The Reverend Jennie Johnson and African Canadian History, 1868–1967The Reverend Jennie Johnson and African Canadian History, 1868–1967. Nina Reid-Maroney. Rochester, NY: University of Rochester Press, 2013. Pp. x + 186, US $90.00 cloth." Canadian Historical Review 96, no. 2 (2015): 313–15. http://dx.doi.org/10.3138/chr.96.2.br13.
Full text
22
Boyden, Joseph. "Dispersed but Not Destroyed: A History of the Seventeenth-Century Wendat PeopleDispersed but Not Destroyed: A History of the Seventeenth-Century Wendat People. Kathryn Magee Labelle. Vancouver: UBC Press, 2013. Pp. 273, $95.00 cloth, $32.95 paper." Canadian Historical Review 96, no. 3 (2015): 424–26. http://dx.doi.org/10.3138/chr.96.3.br01.
Full text
23
Talbot, Robert J. "‘A Justifiable Obsession’: Conservative Ontario's Relations with Ottawa, 1943–1985, by P.E. Bryden‘A Justifiable Obsession’: Conservative Ontario's Relations with Ottawa, 1943–1985. P.E. Bryden. Toronto: University of Toronto Press, 2013. Pp. 340, $75.00 cloth, $34.95 paper and ebook." Canadian Historical Review 96, no. 4 (2015): 626–29. http://dx.doi.org/10.3138/chr.96.4.br15.
Full text
24
Enko, Dietmar, Franz Wallner, Achim von-Goedecke, Christa Hirschmugl, Vinzenz Auersperg, and Gabriele Halwachs-Baumann. "The Impact of an Algorithm-Guided Management of Preoperative Anemia in Perioperative Hemoglobin Level and Transfusion of Major Orthopedic Surgery Patients." Anemia 2013 (2013): 1–9. http://dx.doi.org/10.1155/2013/641876.
Full textAbstract:
The aim of this study was to evaluate a laboratory-guided therapeutic algorithm of preoperative anemia. 335 patients with elective hip or knee arthroplasty were included in this retrospective before-after study. Group I (n= 101) underwent conventional preoperative procedures before algorithm implementation. Group II (n= 234) underwent algorithm-guided preoperative anemia management. A hemoglobin-level of 13 g/dL was the therapeutic cut-off for men and women. Reticulocyte hemoglobin content (CHr) and soluble transferrin receptor (sTfR)/log ferritin ratio were used in the form of the Thomas plot. Iron deficiency (ID) was substituted with 1000 mg iron intravenous (i.v.) and 10000 international units (I.U.) of erythropoiesis-stimulating agent (ESA) subcutaneous (s.c.) or i.v., anemia of chronic disease (ACD) (without functional ID) with 40000 I.U. ESA s.c. or i.v and additionally 200 mg iron i.v. Substituted anemic patients in Group II (n=32) showed a distinctly higher preoperative (Hb-median 13 versus 11.95 g/dL) (P<0.01) and postoperative (Hb-median 9.75 versus 9.0 g/dL) (P<0.05) Hb level compared with untreated anemic patients in Group I (n=24). In Group II red blood cell (RBC) units (35 units/234 patients) were reduced by 44% compared with Group I (27 units/101 patients). Algorithm-guided preoperative anemia management raises perioperative Hb-level and reduces blood use.
25
Bryce, Benjamin. "Village among Nations: “Canadian” Mennonites in a Transnational World, 1916–2006 by Royden LoewenVillage among Nations: “Canadian” Mennonites in a Transnational World, 1916–2006. Royden Loewen. Toronto: University of Toronto Press, 2013. Pp. ix + 301, $75.00 cloth, $32.95 paper." Canadian Historical Review 97, no. 1 (2016): 123–25. http://dx.doi.org/10.3138/chr.97.1.br05.
Full text
26
Cole Young, Liam. "Emergence and Empire: Innis, Complexity, and the Trajectory of History by John BonnettEmergence and Empire: Innis, Complexity, and the Trajectory of History. John Bonnett. Montreal and Kingston: McGill-Queen's University Press, 2013. Pp. ix+371, $110.00 cloth, $34.95 paper." Canadian Historical Review 99, no. 2 (2018): 314–17. http://dx.doi.org/10.3138/chr.99.2.br14.
Full text
27
Santorsola, Domenico, and Elisabetta Abruzzese. "Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review." Mediterranean Journal of Hematology and Infectious Diseases 7 (February 12, 2015): e2015020. http://dx.doi.org/10.4084/mjhid.2015.020.
Full textAbstract:
We report a case of a young patient with HBV hepatopathy, diagnosed with CML in March 2006 and treated with imatinib 400mg/die as first line therapy with concomitant Lamivudine. Patient obtained a complete hematologic response (CHR) in 2 months, complete cytogenetic response (CCyR) in six months and major molecular response (MMR) at 24 months. After three years of treatment she became imatinib intolerant and resistant. In November 2009 patient started nilotinib 400mg/BID. Patient tolerated well the new molecule never experiencing hepatic impairment. After switching to nilotinib she reached in 12 months transcript reduction more than 3 log (MMR). Even if patient had been informed of the need of continuous therapy and to use effective methods of contraception during TKI treatment, in 2012 she decided to plan a pregnancy. In August 2012 a MR4 was documented and treatment discontinued before starting pregnancy. She was observed throughout her pregnancy. The disease remained stable achieving an undetectable transcript level; she delivered a healthy boy in September 2013. Treatment with nilotinib was re-started three months after delivery and she is still in molecular remission (MR5). A complete discussion of the case and the available literature will be presented.
28
DUAN, YI-FAN, and Libing Zhang. "Notes on the fern flora of Fiji: Synonymization of Ctenitis minima and Dryopteris waiwaiensis with Tectaria dissecta (Tectariaceae) and Deparia boryana (Athyriaceae), respectively." Phytotaxa 218, no. 2 (2015): 197. http://dx.doi.org/10.11646/phytotaxa.218.2.13.
Full textAbstract:
Ctenitis C. Christensen (1938: 544) is a fern genus in Dryopteridaceae (Smith et al. 2006, Zhang et al. 2013), containing about 150 species distributed in the New and Old World wet tropics (Mickel & Smith, 2004). While working on a monograph of Ctenitis of the Old World, we found two new synonyms for the fern flora of Fiji which do not belong to Ctenitis and have never been correctly treated before: Ctenitis minima Brownlie (1977: 303), a heterotypic synonym of Tectaria dissecta (G. Forst.) Lellinger (1968: 156) (Tectariaceae), and Ctenitis waiwaiensis (C. Chr.) Brownlie (1977: 303) [basionym: Dryopteris waiwaiensis Christensen (1905: 300)], a heterotypic synonym of Deparia boryana (Willdenow) M. Kato (1977: 36) (Athyriaceae).
29
Mann, Jatinder. "Taking Liberties: A History of Human Rights in Canada, edited by David Goutor and Stephen HeathornTaking Liberties: A History of Human Rights in Canada. Edited by David Goutor and Stephen Heathorn. Don Mills, on: Oxford University Press, 2013. Pp. 304, $35.00 cloth." Canadian Historical Review 98, no. 1 (2017): 182–84. http://dx.doi.org/10.3138/chr.98.1.br17.
Full text
30
Beitāne, Ilze, and Inga Ciproviča. "Nutritional Benefits of Bifidobacterium Lactis in Dairy Products." Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences 67, no. 4-5 (2013): 378–82. http://dx.doi.org/10.2478/prolas-2013-0064.
Full textAbstract:
Abstract Bifidobacteria are one of the most important probiotics in dairy products. They have positive effects on human health. Nutritional benefits of bifidobacteria are genetically determined and can be promoted with addition of prebiotics. The aim of the present study was to examine the properties of Bifidobacterium lactis in dairy products. Pasteurised milk, freeze-dried starter culture Bb-12 (Bifidobacterium lactis, Chr. Hansen, Denmark), syrup of lactulose (Duphalac®, the Netherlands), and inulin (“Raftiline®HP”, ORAFI, Belgium) were used in the experiments. The optimal concentrations of lactulose (2%) and inulin (4%) were established in preliminary studies, based on quality indices and nutritional value of fermented dairy products (Beitane, 2008). Amino acids, carbohydrates, such as lactose, lactulose and inulin, as well as cholesterol were determined during the study using appropriate analytical procedures. The enzymatic activity of bifidobacteria determines nutritional value of the fermented dairy products. Addition of 2% lactulose resulted in significant increase of some amino acid concentrations, such as leucine, phenylalanine, lysine and arginine concentrations (P < 0.05), compared with those in other treatments. The presence of prebiotics caused a decrease of cholesterol level by 35% and lactose content by 31% in fermented milk samples. The enzymatic activity of bifidobacteria should be promoted with addition of lactulose and inulin to increase nutritional value of functional dairy products.
31
Sirks, A. J. B. "Spätantike Zwangsverbände zur Versorgung der römischen Bevölkerung, Rechtshistorische Untersuchungen zu Codex Theodosianus 13.5–9 sowie 14.2–4, written by Chr. Heuft, 2013." Tijdschrift voor rechtsgeschiedenis 84, no. 1-2 (2016): 335–42. http://dx.doi.org/10.1163/15718190-08412p11.
Full text
32
Shingubara, Ryo, Atsuko Sugimoto, Jun Murase, et al. "Multi-year effect of wetting on CH<sub>4</sub> flux at taiga–tundra boundary in northeastern Siberia deduced from stable isotope ratios of CH<sub>4</sub>." Biogeosciences 16, no. 3 (2019): 755–68. http://dx.doi.org/10.5194/bg-16-755-2019.
Full textAbstract:
Abstract. The response of CH4 emission from natural wetlands due to meteorological conditions is important because of its strong greenhouse effect. To understand the relationship between CH4 flux and wetting, we observed interannual variations in chamber CH4 flux, as well as the concentration, δ13C, and δD of dissolved CH4 during the summer from 2009 to 2013 at the taiga–tundra boundary in the vicinity of Chokurdakh (70∘37′ N, 147∘55′ E), located on the lowlands of the Indigirka River in northeastern Siberia. We also conducted soil incubation experiments to interpret δ13C and δD of dissolved CH4 and to investigate variations in CH4 production and oxidation processes. Methane flux showed large interannual variations in wet areas of sphagnum mosses and sedges (36–140 mg CH4 m−2 day−1 emitted). Increased CH4 emission was recorded in the summer of 2011 when a wetting event with extreme precipitation occurred. Although water level decreased from 2011 to 2013, CH4 emission remained relatively high in 2012, and increased further in 2013. Thaw depth became deeper from 2011 to 2013, which may partly explain the increase in CH4 emission. Moreover, dissolved CH4 concentration rose sharply by 1 order of magnitude from 2011 to 2012, and increased further from 2012 to 2013. Large variations in δ13C and δD of dissolved CH4 were observed in 2011, and smaller variations were seen in 2012 and 2013, suggesting both enhancement of CH4 production and less significance of CH4 oxidation relative to the larger pool of dissolved CH4. These multi-year effects of wetting on CH4 dynamics may have been caused by continued soil reduction across multiple years following the wetting. Delayed activation of acetoclastic methanogenesis following soil reduction could also have contributed to the enhancement of CH4 production. These processes suggest that duration of water saturation in the active layer can be important for predicting CH4 emission following a wetting event in the permafrost ecosystem.
33
Klejn, Leo. "Stanford conversations about archaeology (Rathje W. L., Shanks M., Witmore Chr. (eds.). Archaeology in the Making: Conversations Through a Discipline. New York & London: Routledge, 2013. 418 p.)." Prehistoric Archaeology. Journal of Interdisciplinary Studies 2 (2019): 122–25. http://dx.doi.org/10.31600/2658-3925-2019-2-122-125.
Full text
34
Bonifacio, Massimiliano, Chiara Elena, Mariella D'Adda, et al. "Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations." Blood 136, Supplement 1 (2020): 43–44. http://dx.doi.org/10.1182/blood-2020-139826.
Full textAbstract:
Background. The Philadelphia (Ph) chromosome (chr.) is the hallmark of chronic myeloid leukemia (CML) and typically results from the reciprocal translocation t(9;22)(q34;11.2). Complex variant translocations (CVT) involving one or more additional chr. are identified in less than 5% of newly diagnosed CML. There are conflicting reports about the prognostic impact of CVT in the achievement of optimal response to tyrosine kinase inhibitor (TKI), and very few studies addressed the role of frontline treatment with imatinib or second generation (2G)-TKI in patients with CVT. Aims. To assess the response to imatinib or 2G-TKI in a large cohort of newly diagnosed CML with CVT, and to explore the impact of the different chr. translocations on outcome. Methods. This observational retrospective study was conducted in 19 hematologic centers in the framework of Campus CML, a network of Italian physicians involved in the management of CML patients. All newly diagnosed CML from 2000 to 2019 were evaluated and patients with CVT were selected for the present analysis. Karyotypes were defined according to the 2016 International System for Human Cytogenetic Nomenclature. Responses to frontline treatment were retrospectively categorized according to the 2013 ELN recommendations, as they include cytogenetic milestones. Deep molecular response (DMR, i.e. MR4or better) was defined as BCR-ABLIS ratio ≤0.01% or undetectable disease with ≥10,000 ABL copies. Patients with DMR lasting ≥2 years and at least a Q-PCR test every 6 months were defined as stable DMR responders. Failure-free survival (FFS) was calculated from the start of frontline TKI treatment to progression to advanced phase, death, or switch to other treatments for resistance. For FFS calculation, patients were censored at TKI stop for treatment-free remission (TFR) or in case of switch for intolerance only. Differences between subgroups according to the partner chr. were presented for descriptive purposes. Results. CVT were identified in 109 (3.2%) patients from a whole population of 3,361 subjects with newly diagnosed CML. Ninety-five out of 109 patients (87%) exhibited three-way translocations, with chr. 1, 4, 6, 10, 11, 12, 14, 15 and 17 representing the most common additional partners (figure). Four- and five-way translocations were identified in 13 and 1 patients, respectively. Additional chr. abnormalities (ACA) in the Ph+ cells were observed in 15/109 (13.8%) patients and were more common in older individuals (p=0.018). Overall, median age at diagnosis was 50.6 years (range 20-90). Risk distribution according to the ELTS score was 54%, 28% and 8% for L, I and H risk, respectively (10% missing). Cytogenetic result was available before the choice of frontline treatment in 45% of cases and represented a decisive factor in 28% of them (i.e. clinicians selected a 2G-TKI or high-dose imatinib, according to the available options). Frontline TKI treatment was imatinib in 80 cases (73%) and 2G-TKI (nilotinib n=22, dasatinib n=6, bosutinib n=1) in the remaining cases. The frequency of optimal response at 3, 6 and 12 months was 48%, 45% and 53%, respectively, for imatinib-treated patients, and 76%, 83% and 76%, respectively, for the 2G-TKI cohort (p&lt;0.05 for all comparisons). Stable DMR was achieved by 39% of patients and 42% of them attempted a TFR. After a median follow-up of 91.3 months (range 1-236), 5-year FFS was 66% (95%CI: 53.4-76.4) and 84% (95%CI: 62.4-93.6) for imatinib and 2G-TKI treated patients, respectively (p=ns). The estimated 10-year OS for the entire cohort was 84.4% (95%CI: 73.6-91). The subtype of CVT had an impact on response and long-term outcome. Patients with CVT involving chr. 1, 4, 6, 11 or 12 had a higher frequency of MMR at 12 months than patients with CVT involving chr. 10, 14, 15 or 17 (75.8% vs 30.4%, respectively, p=0.001), higher frequency of stable DMR (48.7% vs 22.2%, respectively; p=0.04) and tended to have better median FFS (p=0.07), regardless of the type of frontline TKI and of the ELTS score. Conclusions. Due to its retrospective nature, this study does not allow to define which is the optimal therapy for CML harboring CVT at diagnosis. However, our data reinforce the usefulness of bone marrow karyotyping in CML. The observed differences between partner chr. may also depend on the breaking points, which are variable. Further dissection of CVT will help to identify which are associated to a poor response to TKIs. Figure Disclosures D'Adda: Incyte: Other: Advisory board; Novartis: Other: Advisory board; Pfizer: Other: Advisory board. Galimberti:Novartis: Speakers Bureau; Incyte: Honoraria. Crugnola:Celgene: Honoraria; Janssen: Honoraria; BMS: Honoraria; Novartis: Honoraria. Bocchia:Incyte: Honoraria; CELGENE: Honoraria. Krampera:Janssen: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Breccia:Incyte: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Abbvie: Consultancy; Bristol-Myers Squibb/Celgene: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Saglio:Novartis: Research Funding; Ariad: Research Funding; Pfizer: Research Funding; Bristol-Myers Squibb: Research Funding; Incyte: Research Funding; Roche: Research Funding.
35
Papayannidis, Cristina, Anna Ferrari, Stefania Paolini, et al. "Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome." Blood 124, no. 21 (2014): 484. http://dx.doi.org/10.1182/blood.v124.21.484.484.
Full textAbstract:
Abstract Background: AML is a heterogeneous disease. The karyotype provides important prognostic information that influences therapy and outcome. Identification of AML patients (pts) with poor prognosis such as those with complex karyotype (CK) has great interest and impact on therapeutic strategies. TP53 is the most frequently mutated gene in human tumours. TP53 mutation rate in AML was reported to be low (2.1%), but the incidence of TP53 mutations in AML with a complex aberrant karyotype is still debated. Aims: To investigate the frequency of TP53 mutations in adult AML pts, the types of mutations, the associations with recurrent cytogenetic abnormalities and their relationship with response to therapy, clinical outcome and finally their prognostic role. To this aim, we focused on a subgroup of TOT/886 AML pts treated at the Serˆgnoli Institute of Bologna between 2002 and 2013. Patients and Methods: 886 AML patients were analysed for morphology, immunophenotype, cytogenetic and for a panel of genetic alterations (FLT3, NPM1, DNMT3A, IDH1, IDH2 mutations, WT-1 expression, CBF fusion transcripts). Of these, 172 adult AML pts were also examined for TP53 mutations using several methods, including Sanger sequencing, Next-Generation Deep-Sequencing (Roche) and HiSeq 2000 (Illumina) platform. 40 samples were genotyped with Genome-Wide Human SNP 6.0 arrays or with CytoScan HD Array (Affymetrix) and analysed by Nexus Copy Numberª v7.5 (BioDiscovery). Results: Of the 886 AML patients, 172 pts were screened for TP53 mutations. Sanger sequencing analysis detected TP53 mutations in 29/172 AML patients with 36 different types of mutations; seven pts (4%) had 2 mutations. At diagnosis, the median age of TP53 mutated and wild type patients was 68 years (range 42-86), and 65 years (range 22-97) respectively. Median WBC count was 8955/mmc (range 580-74360/mmc) and 1240/mmc (range 400-238000/mmc). Conventional cytogenetics showed that: a) 52 pts (30,2%) had 3 or more chromosome abnormalities, i.e. complex karyotype; b) 71 (41,3%) presented with one or two cytogenetic abnormalities (other-AML); c) 34 pts (19,8%) had normal karyotype. Most of the TP53 mutated pts (23/29, 79.3%) had complex karyiotype, whereas only 6/29 mutated pts had “no complex Karyotype” (21% and 3% of the entire screened population, respectively). Overall, TP53 frequency was 44.2% in the complex karyotype group, suggesting a pathogenetic role of TP53 mutations in this subgroup of leukemias. As far as the types of TP53 alterations regards, the majority of mutations (32) were deleterious.. Copy Number Alterations (CNAs) analysis performed on 40 cases by Affymetrix SNP arrays showed the presence of several CNAs in all cases: they ranged from loss or gain of the full chromosome (chr) arm to focal deletions and gains targeting one or few genes involving macroscopic (>1.5 Mbps), submicroscopic genomic intervals (50 Kbps - 1.5 Mbps) and LOH (>5 Mbps) events. Of relevance, gains located on chr 8 were statistically associated with TP53 mutations (p = 0.001). In addition to the trisomy of the chr 8, others CNAs, located on chromosomes 5q, 3, 12, 17 are significantly associated (p = 0.05) with TP53 mutations. WES analysis was performed in 37 pts: 32 TP53 were wt while 5 pts were TP53 mutated. Interestingly, TP53 mutated patients had more incidence of complex karyotype, more aneuploidy state, more number of somatic mutations (median mutation rate 30/case vs 10/case, respectively). Regarding the clinical outcome, as previously reported (Grossmann V. et Al. Blood 2013), alterations of TP53 were significantly associated with poor outcome in terms of both overall survival (median survival: 4 and 31 months in TP53 mutated and wild type patients, respectively; p<0.0001) and relapse free-survival (RFS) (p < 0.0001). (Figure 1) Figure 1: Overall Survival curve of 172 AML patients with (red) or without (blue) TP53 mutations (p< 0.0001). Conclusions: Our data demonstrated that TP53 mutations are more frequent at diagnosis in the subgroup of complex karyotype AML (16.86%) (p< 0.0001–Fisher's exact test). They are mostly deleterious mutations and are significantly correlated with worst prognosis, fail to respond to therapy and rapidly progress. We recommend TP53 mutation screening at least in AML pts carrying either complex karyotype or chr. 8 gain. Supported by: ELN, AIL, AIRC, PRIN, progetto Regione-Universitˆ 2010-12 (L. Bolondi), FP7 NGS-PTL project. Disclosures No relevant conflicts of interest to declare.
36
Youssef, Lama A., Issam N. Albaroudi, and Majed Khodder. "Prevalence of Iron Deficiency and Iron Deficiency Anemia in Syrian Infants." Blood 124, no. 21 (2014): 5975. http://dx.doi.org/10.1182/blood.v124.21.5975.5975.
Full textAbstract:
Abstract Background: Iron deficiency (ID), with or without anemia, is the most common micronutrient malnutrition problem worldwide. Iron deficiency anemia (IDA) in infancy is linked to long-term motor and cognitive deficits. Infants and children in developing countries are particularly vulnerable to ID due to a negative iron balance resulting from increasing demands for growth that surpass dietary supplies. Recently, health reports have emerged on rising child malnutrition due to shortages of children’s foods and medicines in Syria. Nevertheless, factual data on prevalence are lacking. Objective: To estimate the prevalence of ID and IDA in a cohort of non-displaced Syrian infants living in Damascus between November, 2011 and March, 2013. Design/Methods: This was a prospective observational study conducted at the Children’s Hospital-based primary care clinic in Damascus. Information on type of feeding milk (maternal, iron-fortified formula or cow milk), and demographic characteristics was collected by face-to-face interviews with the parents of the study subjects. Hematological profile (complete blood count, reticulocytes and reticulocyte hemoglobin content (CHr)), and biochemical tests including serum ferritin and iron, and total iron-binding capacity were carried out. ID and IDA were diagnosed according to the 2010 American Academy of Pediatrics guidelines. Results: Out of 155 infants assessed for eligibility, 135 infants met the inclusion criteria and were evaluated for iron deficiency. The average age was 12.4 ± 5.5 months (mean ± SD), and female to male ratio was 57:78. Only 31 (23%) of the study subjects were iron sufficient and not anemic, whereas 97 (72%) had ID, 75 (55.5%) had IDA, and 7 (5.2%) had non-iron deficiency anemia (thalassemia, hemolytic anemia, and macrocytic anemia). Prevalence of ID was statistically higher in males than females (85.33% vs. 62.26% respectively) (P=0.003). IDA was more prevalent in infants living in the countryside (76.25%) in comparison with their urban peers (53.84%) (p=0.04). Unexpectedly, ID and IDA were similarly prevalent regardless of the predominant type of milk fed to the infants (P >>0.05). Conclusion: Our results unveil high prevalence of ID and IDA in Syrian infants between 2011 and 2013. Higher rates are expected in displaced infants and in remote regions of the country. These alarming findings call for immediate national and international collaborative efforts to provide iron supplementation and correct other existing malnutrition in Syrian children. Disclosures No relevant conflicts of interest to declare.
37
Meng, H. N., C. C. Song, Y. Q. Miao, R. Mao, and X. W. Wang. "Response of CH<sub>4</sub> emissions to moss removal and N addition in boreal peatland of northeast China." Biogeosciences 11, no. 17 (2014): 4809–16. http://dx.doi.org/10.5194/bg-11-4809-2014.
Full textAbstract:
Abstract. Boreal peatlands are an important natural source of atmospheric methane (CH4). Recently, boreal peatlands have been experiencing increased nitrogen (N) availability and decreased moss production. However, little is known about the interactive effect of moss and N availability on CH4 emissions in boreal peatlands. In this study, the effects of moss removal and N addition (6 g N m−2 yr−1) on CH4 emissions were examined during the growing seasons of 2011, 2012 and 2013 in a boreal peatland in the Great Hinggan Mountain of northeast China. Notably, the response of CH4 emissions to moss removal and N addition varied with experimental duration. Moss removal and N addition did not affect CH4 emissions in 2011 and 2012, but respectively reduced CH4 emissions by 50% and 66% in 2013. However, moss removal and N addition did not produce an interactive effect on CH4 emissions. Consequently, moss removal plus N addition had no effect on CH4 emissions in 2011 and 2012, but decreased CH4 emissions by 68% in 2013. These results suggest that the effects of moss removal and N enrichment on CH4 emissions are time-dependent in boreal peatlands, and also imply that increased N availability and decreased moss growth would independently inhibit CH4 emissions in the boreal peatlands of northeast China.
38
Hömberg, Walter. "Gerhard Chr. Bukow / Johannes Fromme / Benjamin Jörissen (Hrsg.) (2012): Raum, Zeit, Medienbildung. Untersuchungen zu medialen Veränderungen unseres Verhältnisses zu Raum und Zeit. Wiesbaden: Springer VS." Medien & Kommunikationswissenschaft 61, no. 4 (2013): 596–97. http://dx.doi.org/10.5771/1615-634x-2013-4-596.
Full text
39
Borlenghi, Erika, Chiara Pagani, Claudia Basilico, et al. "Validating the Patient's "Fitness" Criteria Proposed to Guide Treatment Decision in Elderly AML: a Multicenter Study on a Population-Based Series of 362 Patients By the Network "Rete Ematologica Lombarda" (REL)." Blood 124, no. 21 (2014): 279. http://dx.doi.org/10.1182/blood.v124.21.279.279.
Full textAbstract:
Abstract BACKGROUND: Median age of patients (pts) with acute myeloid leukemia (AML) ranges between 69 and 72 years in population-based series (SEER, 2012; Juliusson, 2009). The prognosis of elderly AML is exceedingly poor with overall 2-year survival of 10% (Juliusson, 2011). The use of intensive chemotherapy (i-CT) in elderly AML patients as opposed to non-intensive chemotherapy (ni-CT) or best supportive care (BSC) is still debated. Age is still the major driver of treatment choice but, in recent years, the role of pts' fitness and comorbidities was underscored. In 2013, a panel of experts proposed a set of objective criteria to define pts fit or unfit to conventional i-CT, ni-CT or BSC (Ferrara et al, Leukemia, 2013). Since such criteria derived from experts opinion, they need to be validated in the clinical setting to become an useful tool for therapy decision making. AIMS: Fitness criteria were retrospectively applied to a population-based series of pts with AML (no M3), to evaluate a) their actual applicability; b) the concordance between fitness categorization of pts and the type of treatment they actually received; c) the outcome of pts according to fitness, to the prognostic stratification of European Leukemianet (ELN) and to the treatment received. PATIENTS and METHODS. We evaluated 362 pts aged > 65 y, diagnosed at five Hematology Centres of the Hematological Network of Lombardy in Northern Italy (REL). Pts were diagnosed between January 2008 and May 2014. Their median age was 73 y (range 65-94 y). Their categorization according to fitness criteria was carried out retrospectively by the teams of physicians who had followed pts and through medical files. Pts were classified as fit to i-CT (FIT), unfit to i-CT (UNFIT), or unfit even to ni-CT (FRAIL). According to ELN prognostic criteria, applied in 201 de novo AML, pts were at low-risk (36 pts: 18%), of which 7 (3,4%) with CBF leukemia, intermediate-I (75 pts: 37%), intermediate-II (30 pts: 15%), or high risk (60 pts: 30%). Criteria were not applicable in 34 pts (14%) lacking karyotype or molecular data. The group of 127 pts (35%) with AML therapy-related or secondary to myeloid neoplasms was considered at high clinical risk (cHR). According to physicians decision, 139 pts (38.4%) had received i-CT, 65 pts (18%) ni-CT, including low-dose arac, azacytidine or experimental non-myelotoxic drugs, and 158 pts (43.6%) BSC. RESULTS. Fitness criteria were not applicable in 12 pts (3%), because of insufficient data. Among 350 evaluable pts (97%), 170 (46.9%) were FIT, 140 (38.7%) were UNFIT, and 40 (11%) were FRAIL. Their median age was 69, 79 and 75 years, respectively (p <0.0001). Median overall survival (OS) of FIT, UNFIT and FRAIL pts was 12.5, 3.7 and 1.8 months, respectively (FIT vs others: P=0.0001, UNFIT vs FRAIL: p=0.049) (Figure 1). Overall concordance between fitness criteria and the treatment actually received by pts was 80% (71% in FIT, 88% in UNFIT and 90% in FRAIL pts). Median OS of pts receiving i-CT, ni-CT or BSC was 14.7, 14.2 and 4.2 months in FIT, (p<0.0001), 8.6, 8.9, 2 months in UNFIT (p<0.0001) (i-CT vs ni-CT: P:NS), respectively. Median OS inFRAIL pts receiving ni-CT (4 pts only) or BSC was 11.5 and 2 months, respectively (p:NS). Considering pts receiving i-CT, their outcome was significantly related both to ELN/clinical risk and to fitness. CR rate was 96.5% in LR, 66% in Int-I, 54% in Int-II, 46% in HR, 53% in cHR (p=0.0013). OS at 2y was 40% in LR/Int-I vs 25% in Int-II/HR/cHR pts (P=0.04). Median OS was 14.7 in FIT vs 8.6 months in UNFIT/FRAIL pts (P=0.022). By integrating ELN prognostic stratification with fitness, the use of i-CT obtained a significantly better median OS of 20 months in FIT pts at ELN LR/Int-I compared to 8,5 months in pts at Int-II/HR/cHR (p 0.014) (Figure 2). CONCLUSIONS. The fitness criteria proposed were easily applicable even retrospectively and in a multicenter setting. Fitness was significantly related to patient's survival. In FIT and UNFIT pts outcome was similar with either i-CT or ni-CT, but these results need to be tested prospectively on larger cohorts. Integrating fitness with ELN criteria identifies a subgroup of FIT pts at low/Int-I ELN risk with a CR rate of 76.6% and a median OS of 20 months when treated with i-CT. Therefore fitness criteria seem to be a good tool to identify pts who can benefit from i-CT or ni-CT in alternative to BSC and to assist in the decision to use i-CT in elderly AML patients. Figure 1 Figure 1. Figure 2 Figure 2. Disclosures No relevant conflicts of interest to declare.
40
Jazza, Salih Hassan, Abdul-Hussain Y. Al-Adhub, and Hamid T. Al-Saad. "Polycyclic Aromatic Hydrocarbons (PAHs) in Muscles of Two Commercial Fish Species from Al-Kahlaa River in Missan Governorate, Iraq." ILMU KELAUTAN: Indonesian Journal of Marine Sciences 20, no. 3 (2015): 121. http://dx.doi.org/10.14710/ik.ijms.20.3.121-126.
Full textAbstract:
Al-Kahlaa River is one of main tributaries of the Tigris River in Missan city and rises from northwest side of Amara city and continues to flow in the direction to the east of city center. Two commercial fish species (Liza abu and Carassius auratus) were collected seasonally (autumn, winter, spring and summer) during period from 2012 to 2013 from Al-Kahlaa River in Missan governorate. The concentrations of Polycyclic Aromatic Hydrocarbons (PAHs) in fish muscles were determined in the laboratories of Nihran Omer (South Oil Company in Basrah province), using Gas Chromatography. Total concentrations of PAHs in muscles of L. abu ranged between 2.301 and 16.661 ng.g-1 dry weight during winter and summer respectively and in C. auratus between 1.095 and 8.675 ng.g-1 dry weight during winter and summer, respectively. Results of this study revealed that high molecular weight of PAHs were more than low molecular weight in both fish species, and according to ratios of Low molecular weight Polycyclic Aromatic Hydrocarbons (LPAHs) to High molecular weight Polycyclic Aromatic Hydrocarbons (HPAHs), Benzo(a) Anthracene /(Benzo(a) Anthracene+ Chrysene) BaA/(BaA+Chr),Indeno (1,2,3-cd) pyrene /(Indeno (1,2,3-cd) pyrene + Benzo (ghi) perylene) InP/(InP+BghiP) and Fluoranthene/Pyrene (Fl/Py), they certainly reflected that the PAHs sources in both species are pyrogenic as a main sources and petrogenic as a small part. Also results of this study revealed the presence of seasonal variations in total concentrations of PAHs in both fish species. The study area was generally contaminated with hydrocarbons and continuous consumption of food from this area may pose public health hazards. Keywords: polycyclic aromatic hydrocarbons, PAHs, fish, pollution Al-Kahlaa adalah salah satu anak sungai utama Sungai Tigris di kota Missan dari sisi barat laut kota Amara dan terus mengalir ke arah ke timur dari pusat kota. Dua spesies ikan komersial (Liza abu dan Carassius auratus) diperoleh pada musim berbeda (gugur, dingin, semi dan panas) selama periode 2012-2013 dari Al-Kahlaa. Konsentrasi polisiklik aromatik hidrokarbon (PAH) pada otot ikan dianalisis di laboratorium Nihran Omer (South Oil Company di provinsi Basrah), menggunakan Gas Chromatography. Total konsentrasi PAH pada otot L. abu berkisar antara 2,301 dan 16,661 ng.g-1 berat kering pada musim dingin dan musim panas. Sedangkan pada C. auratus antara 1,095 dan 8,675 ng.g-1 berat kering pada musim dingin dan musim panas. Hasil penelitian ini menunjukkan bahwa berat molekul tinggi PAH lebih dari berat molekul rendah pada kedua spesies ikan, dan menurut rasio berat molekul rendah polisiklik aromatik hidrokarbon (LPAHs) untuk berat molekul tinggi polisiklik aromatik hidrokarbon (HPAHs), Benzo (a ) Anthracene / (Benzo (a) Anthracene + Chrysene) BAA / (BAA + Chr), Indeno (1,2,3-cd) pyrene / (Indeno (1,2,3-cd) pyrene + Benzo (ghi) perylene) InP / (InP + BghiP) dan fluoranthen / Pyrene (Fl/Py), hal ini mencerminkan bahwa sumber PAH di kedua spesies adalah pirogenik sebagai sumber utama dan petrogenic sebagai bagian kecil. Hasil penelitian ini juga mengungkapkan adanya variasi musiman total konsentrasi PAH di kedua spesies ikan. Daerah penelitian umumnya terkontaminasi dengan hidrokarbon sehingga konsumsi makanan dari daerah ini secara berkelanjutan dapat menimbulkan bahaya kesehatan masyarakat. Kata kunci: polisiklik aromatik hidrokarbon, PAHs, ikan, polusi
41
Meng, H. N., C. C. Song, Y. Q. Miao, R. Mao, and X. W. Wang. "Response of CH<sub>4</sub> emission to moss removal and N addition in boreal peatland of Northeast China." Biogeosciences Discussions 11, no. 2 (2014): 3365–85. http://dx.doi.org/10.5194/bgd-11-3365-2014.
Full textAbstract:
Abstract. Boreal peatlands are an important natural source of atmospheric methane (CH4). Recently, boreal peatlands have been experiencing increased nitrogen (N) input and decreased moss production. However, little is known about the interactive effect of moss and N availability on CH4 emission in boreal peatlands. In this study, the effects of moss removal and N addition (6 g N m−2 yr−1) on CH4 emission were examined during the growing seasons of 2011 to 2013 in a boreal peatland in the Great Hinggan Mountain of Northeast China. Notably, the response of CH4 emission to moss removal and N addition varied with experimental duration. Moss removal and N addition did not affect CH4 emission in 2011 and 2012, but respectively declined CH4 emission by 50% and 66% in 2013. However, moss removal and N addition did not produce an interactive effect on CH4 emission. Specifically, moss removal plus N addition had no effect on CH4 emission in 2011 and 2012, but decreased CH4 emission by 68% in 2013. These results suggest that the effects of moss removal and N enrichment on CH4 emission are time-dependent in boreal peatlands, and also imply that increased N loading and decreased moss growth would independently inhibit CH4 emission in the boreal peatlands of Northeast China.
42
Jazza, Salih Hassan, Abdul Hussain Y. Al-Adhub, and Hamid T. Al-Saad. "Polycyclic Aromatic Hydrocarbons (PAHs) in water of Al-Kahlaa River in Missan Province, Iraq." ILMU KELAUTAN: Indonesian Journal of Marine Sciences 21, no. 1 (2016): 1. http://dx.doi.org/10.14710/ik.ijms.21.1.1-8.
Full textAbstract:
The present study was performed to have knowledge of Polycyclic Aromatic Hydrocarbonspollution status in water. The samples were collected during two seasons (winter and summer 2012 ,2013) from four different stations) Al-Magideh, Treatment unit, Al-Husaichi and Al-Zubair) distributed along Al-KahlaaRiver in Missan province, in addition to reference station lies on the Tigris river before 25 Km from entering to Amara city. The concentrations of PAHs were determined in by using capillary Gas Chromatography. Results of the present study revealed that the total concentrations of PAHs in dissolved fraction ranged from 0.739 ng.l-1 in Reference station to 1.974 ng.l-1 in Treatment unit during winter, and from 0.300 ng.l-1 in Reference station to 1.125 ng.l-1 in Treatment unit during summer, while in the particulate fraction they varied from 0.79 ng.g-1 dry weight in Reference station to 24.42 ng.g-1 dry weight in Treatment unit during winter, and from 4.369 ng.g-1 dry weight in Reference station to 10.545 ng.g-1 dry weight in Al-Husaich during summer. It had been noticed that there were a predominance of high molecular weight PAHs on low molecular weight, while BaA/(BaA+Chr) ratio in water ranged from 0.218 to 0.804. InP/(InP+BghiP) ratio ranged between 0 and 0.578,whereas Fl/Pyratio ranged between 0.150 and 2 ,this give an indication of the origin of PAHs compounds in water which were mainly pyrogenic and few from them petrogenic. Keywords: polycyclic aromatic hydrocarbons, PAHs, water, pollution
43
Hidayati, Lina Nur. "Pengaruh Kecukupan Modal (CAR), Pengelolaan Kredit (NPL), dan Likuiditas Bank (LDR) Terhadap Probabilitas Kebangkrutan Bank (Studi pada Bank Umum Swasta Devisa yang tercatat di BEI tahun 2009 – 2013)." JURNAL ILMU MANAJEMEN 12, no. 1 (2015): 38–50. http://dx.doi.org/10.21831/jim.v12i1.11741.
Full textAbstract:
The purpose of this research is to provide empirical evidence about using bank financial ratio to predict bank bankruptcy. The variables which used are seven financial ratios, CAR (capital adequacy ratio), NPL (non performing loan), and LDR (loan to deposit ratio). The statistic methods which is used to test on the research hypothesis is logit regression.The sample of this research was extracted using purposive sampling method, comprising 7 banks taken from BEI for the period of 2009, 2010, 2011, 2012, 2013. From sample, there are 7 banks, consist of 4 nontrouble banks and 3 trouble banks. The resulst of this research show that CAR and NPL, have no significant effect on probability of banks’s financial distress. LDR have significant influences on probability of banks’s financial distress.Keywords :
44
Sugino, Masato. "CAR-BOREN SURVEY ON AMBIENT DOSE RATE DURING 2011–13 IN GUNMA PREFECTURE." Radiation Protection Dosimetry 184, no. 3-4 (2019): 347–50. http://dx.doi.org/10.1093/rpd/ncz101.
Full textAbstract:
Abstract A car-borne survey of air dose rate measurements was performed yearly from 2011 to 2013 to determine the levels of environmental radiation in Gunma prefecture after the Fukushima Daiichi Nuclear Power Plant accident in 2011. The results revealed that the average ambient doses in each year were 85.3 ± 34.1 nGy/h in 2011, 60.3 ± 19.9 nGy/h in 2012, and 43.5 ± 15.1 nGy/h in 2013. The ambient dose rate in 2011, which was about three times higher than the average of 27.0 ± 7.1 nGy/h in 1998, was still in safety level considering the public health, and the ambient dose rate subsequently decreased in 2013 to approximately half the 2011 level. A contour map of the ambient dose rate showed relatively higher levels in the northern and western parts of the prefecture, with relatively lower levels toward the eastern and southern parts.
45
BOUKHALFA, Sana, Souhila SLIMANI, Assia LOUNIS, Youcef LALAYMIA, and Salim KHELKHAL. "Consumption of vancomycin at Batna University Hospital, 2017-2018." Batna Journal of Medical Sciences (BJMS) 6, no. 1 (2019): 44–46. http://dx.doi.org/10.48087/bjmsoa.2019.6112.
Full textAbstract:
Objectif. Etudier la consommation de la vancomycine au niveau du CHU de Batna durant une période de 18 mois allant du janvier 2017 jusqu’à juin 2018. Matériels et méthodes. Etude rétrospective sur une période de 18 mois de janvier 2017 au juin 2018. Les taux de consommation de la vancomycine à partir de la base de données de la pharmacie centrale du CHU Batna. Seules les hospitalisations complètes étaient concernées par l’enquête. La journée de traitement antibiotique estimé (JTE) est la quantité exprimée en grammes de principe actif d’un antibiotique consommé divisé par la dose définie journalière (DDJ). Résultats. L’évolution semestrielle de la consommation de vancomycine au CHU Batna a connu une diminution durant la période d’étude : 37,54 DDJ/1000JH le 1er semestre, 34,15 DDJ/1000JH le 2ème semestre et 31,79 DDJ/1000 JH le 3ème semestre. Les services médicaux consommaient moins de vancomycine par rapport aux autres services : 6,66 DDJ/1000 JH durant la période d’étude. Les services d’hématologie, des brûlés et de réanimation médicale étaient les grands consommateurs de vancomycine, dont le service des brûlés occupait la première place : 147,04 DDJ/1000JH. La consommation importante de la vancomycine dans notre établissement était probablement à l’origine de l’émergence de souches d’Enterococcus faecium résistantes à la vancomycine (ERV) en 2017 et 2018. Conclusion. L’exposition souvent inappropriée de la population aux antibiotiques et la transmission interindividuelle des souches résistantes constituent les deux déterminants de l’émergence et de la diffusion des résistances bactériennes aux antibiotiques.
46
Bilukha, Oleg O., Eva Z. Leidman, Abdul-Salam Saleh Sultan, and Syed Jaffar Hussain. "Deaths due to Intentional Explosions in Selected Governorates of Iraq from 2010 to 2013: Prospective Surveillance." Prehospital and Disaster Medicine 30, no. 6 (2015): 586–92. http://dx.doi.org/10.1017/s1049023x15005300.
Full textAbstract:
AbstractIntroductionThe aim of this study was to describe the most recent trends and epidemiologic patterns of fatal injuries resulting from explosions in Iraq, one of the countries most affected by violence from explosive devices.MethodsIraqi Ministry of Health (MoH) routine prospective injury surveillance collects information on all fatal injuries recorded by coroners from physical examinations, police reports, and family members in eight governorates of Iraq: Baghdad, Al-Anbar, Basrah, Erbil, Kerbala, Maysan, Ninevah, and Al-Sulaimaniya. This study analyzed explosive-related fatal injuries that occurred from January 1, 2010 through December 31, 2013.ResultsAnalysis included 2,803 fatal injuries. The number of fatal injuries declined from 2010 through 2012, followed by an increase in 2013. One-thousand one-hundred and one explosion-related fatalities were documented in 2013, more than twice as many as in 2012 or in 2011. Most fatalities were among men aged 20-39 years. Of all causalities, 194 (6.9%) were among females and 302 (10.8%) were among children aged less than 18 years. The majority of fatalities were caused by improvised explosive devices (IEDs): car bombs (15.3%), suicide bombs (4.0%), and other IEDs (29.6%). The highest number of fatalities occurred in streets and roads. Of all deaths, 95.6% occurred in three governorates: Baghdad, Ninevah, and Al-Anbar.ConclusionsExplosives continue to result in a high number of fatal injuries in Iraq. Following a period of declining violence from explosives, in 2013, fatalities increased. Most explosion-related injuries resulted from IEDs; males aged 20-39 years were at greatest risk.BilukhaOO, LeidmanEZ, SultanASS, HussainSJ. Deaths due to intentional explosions in selected governorates of Iraq from 2010 to 2013: prospective surveillance. Prehosp Disaster Med. 2015;30(6):586–592.
47
McDonald-Wharry, John. "2013–2014 Survey of Chars Using Raman Spectroscopy." C 7, no. 3 (2021): 63. http://dx.doi.org/10.3390/c7030063.
Full textAbstract:
In late 2013, an open call for charcoal and biochar samples was distributed in an effort to compare a wide range of char samples by Raman spectroscopy. The samples contributed to this survey included: laboratory produced biochars, recent biochars produced in field conditions, and ancient char samples previously analysed by carbon dating. By using selected Raman measurements, the char samples could be ranked in terms of the degree of thermochemical alteration or extent of carbon nanostructural development. The Raman results for recently produced biomass chars were generally consistent with the conversion of amorphous carbon formed at lower temperatures into condensed, polyaromatic, and graphene-like carbon formed at higher temperatures. A number of parameters calculated from the Raman spectra could be used to estimate the effective heat treatment temperatures in the recently produced biochars. Other samples such as anthracite coal, tire pyrolysis carbon, and ancient chars departed from the trends observed in the recently produced biomass chars using this approach. In total, 45 samples were analysed by Raman spectroscopy for this survey. Ancient and buried char samples displayed higher intensities for features in the Raman spectra associated with amorphous carbon.
48
Palečková, Iveta. "Banking Efficiency in Visegrad Countries: A Dynamic Data Envelopment Analysis." Acta Universitatis Agriculturae et Silviculturae Mendelianae Brunensis 63, no. 6 (2015): 2085–91. http://dx.doi.org/10.11118/actaun201563062085.
Full textAbstract:
The aim of the paper is to examine the efficiency of the banking sectors in Visegrad countries during the period 2009–2013. The group of Visegrad countries includes the Czech Republic, Hungary, Poland and Slovakia. We apply Dynamic Data Envelopment Analysis (DEA) to data on commercial banks in the group of Viserad countries. Next, we calculated average efficiency of the groups of banks according the total assets. Average efficiency was slightly decreased during the period 2010–2011 and significantly decreased in 2012 which was probably as a result of financial crisis. In 2013 average efficiency increased. The Czech and Hungarian banking sector was the highest efficient. Considering the group of banks according total assets, the group of small banks was the most efficient in CCR model and the group of medium-sized banks was the most efficient in BCC model.
49
Harrison, Claire N., Adam Mead, Sonia Fox, et al. "Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia." Blood 128, no. 22 (2016): 1929. http://dx.doi.org/10.1182/blood.v128.22.1929.1929.
Full textAbstract:
Abstract MAJIC is a phase II trial of Ruxolitinib (RUX) vs Best Available Therapy (BAT) in essential thrombocythemia (ET) patients with resistance/intolerance to Hydroxycarbamide (HC) per European LeukemiaNet (ELN) criteria. Primary outcome was rate of complete hematological response (CHR) within 1 year (ELN criteria); secondary outcomes included partial HR, safety, thrombosis, hemorrhage, progression free survival (including transformation), molecular response (MR), symptom & quality of life (QOL) assessment. We present new data concerning molecular, symptom & clinical responses. Patients were stratified by JAK2V617F status, patient-reported symptoms & QOL determined using EQ5D, MDASI & MPN Symptom Assessment Form (MPN10), & compared using linear mixed models of post-baseline scores through month 12 adjusting for baseline; response was defined as ≥50% reduction in MPN10 total symptom score (TSS). JAK2/CALR/MPL allele burdens were assessed at baseline & 4 monthly. 110 patients were eligible for the modified ITT analysis, 58 (52%) & 52 (48%) in RUX & BAT arms respectively, comprising 44 males, 66 females, mean age 64.2ys, & resistant (24.5%), intolerant (51.8%) or both (22.7%) to HC. CHR was achieved in 27 (46.6%) of RUX patients vs 23 (44.2%) BAT patients (χ2 test p= 0.81). PHR occurred in 26 (44.8%) & 27 (51.9%) of RUX & BAT treated respectively. Grade 3 or 4 anemia occurred in 19% & 0% for RUX arm vs 0% (both grades) for BAT arm, grade 3 or 4 thrombocytopenia in 5.2% & 1.7% of RUX vs 0% (both grades) of BAT patients respectively. Grade 3 or 4 infections occurred in 10.3% of RUX patients vs 3.6% BAT arm. 9 RUX treated patients had 10 thrombotic events & 1 RUX patient a hemorrhage; vs 5 thrombotic & 5 hemorrhagic events in BAT patients (adjusted following central review). Transformations to post-ET MF occurred in 8 RUX vs 3 BAT treated patients, 1 RUX patient developed AML. 2 non-treatment related deaths occurred in each arm. Mean MPN-10 TSS & individual symptoms of early satiety & itching during the first 12 months were all significantly lower for RUX vs BAT (all p<0.05). Patients who achieved CHR had significantly better TSS, fatigue, inactivity, concentration problems, & MDASI symptom interference (all p<0.05) at baseline vs those without; however, scores during treatment did not appear to differ between CHR & non CHR groups after adjusting for these baseline differences. Allele burden during study & MRs (per ELN-IWG criteria Barosi Blood 2013) are shown in Table 1. Assays for JAK2 V617F were performed independently in 3 centres using qPCR (Guy's), TSCA NGS (Oxford) & amplicon-based NGS (Salisbury) & revealed Mean (range): JAK2 (Guy's): 33.2 (0.1-94.6), N=52; JAK2 (Oxford): 38.0 (0.5-92.2), N=52; JAK2 (Sal): 38.3 (0-90.0), N=50 (limited to JAK2 positive only). With Interclass Correlation Coefficient as follows ICC (Guy's v Oxford): 0.92 (95% CI 0.86-0.95) ICC (Guy's v Sal): 0.92 (95% CI 0.86-0.95) ICC (Oxford v Sal): 0.997 (95% CI 0.994-0.998). Notably MRs (n=5) only occurred with RUX treatment. There was no pattern of MR or progression with C/PHR or transformation, but 1 patient who transformed to PET MF had a complete MR. In a separate analysis baseline symptoms & QOL were not associated with JAK2, CALR, nor MPL status. Within RUX, baseline symptoms & QOL did not predict MR; however, fatigue, early satiety & abdominal discomfort (all p<0.05, Table 1) were significantly lower among those with MR vs not during treatment with a descriptively higher symptom response rate (2/4 [50%] vs 9/30 [30%]). Three non pre-specified multivariate analyses were performed to assess baseline factors influencing CHR (modelled for: treatment received, HC resistance or intolerance, white cell count, platelets, Hb & JAK2/CALR status); occurrence of ≥ grade 3 anemia or thrombocytopenia (modelled for: Hb (≥ 100g/dl) JAK2/CALR status); & transformation to PET-MF (modelled for: treatment, Hb ≤100g/dl). Only baseline Hb ≤100g/dl was significant for grade 3+ anemia (OR [95% CI]=0.17 [0.04, 0.72]), & PET-MF only occurred in patients with baseline WBC <10x109/L. This updated analysis shows that HC resistant/intolerant ET is clinically & molecularly diverse. We confirm that these patients are at high risk of thrombosis & transformation as suggested in prior retrospective studies. Molecular responses were limited to RUX & for the first time we demonstrate such responses may correlate with symptom improvement but not always with progression events. Disclosures Harrison: Shire: Honoraria, Speakers Bureau; Gilead: Honoraria, Speakers Bureau; Incyte Corporation: Honoraria, Speakers Bureau; Baxaltra: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria, Other: travel, accommodations, expenses, Research Funding, Speakers Bureau. Mead:Novartis: Honoraria, Research Funding, Speakers Bureau. Aliman:Novartis: Other: Institutional funding and grant for international conference. . Chen:Novartis: Other: Advisory Board. Coppell:Novartis: Other: Travel, accommodation and conference attendance. Knapper:ONO pharmaceuticals: Research Funding; Novartis: Honoraria, Other: Travel and expenses for international conferences. Ali:Novartis: Honoraria, Other: Conference sponsorship, advisory board meetings. Hamblin:Novartis: Other: Advisory Board. Dueck:Bayer: Honoraria. Cross:Novartis: Consultancy, Honoraria, Research Funding, Speakers Bureau. Mesa:Celgene: Research Funding; Promedior: Research Funding; CTI: Research Funding; Gilead: Research Funding; Incyte: Research Funding; Galena: Consultancy; Ariad: Consultancy; Novartis: Consultancy. McMullin:Novartis: Honoraria, Speakers Bureau.
50
Bergemann, Johannes. "Nadin Burkhardt, Bestattungsriten zwischen Tradition und Modifikation. Kulturelle Austauschprozesse in den griechischen Kolonien in Unteritalien und Sizilien vom 8. bis zum 5. Jahrhundert v. Chr. (Italika, Bd. 2.) Wiesbaden, Reichert 2013." Historische Zeitschrift 306, no. 2 (2018): 502–4. http://dx.doi.org/10.1515/hzhz-2018-1115.
Full text